{{Rsnum
|rsid=4919908
|Gene=C19orf20
|Chromosome=19
|position=508626
|Orientation=plus
|GMAF=0.4284
|Gene_s=TPGS1
|Assembly=GRCh37.p5
|GenomeBuild=37.3
|dbSNPBuild=137
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 30.1 | 44.2 | 25.7
| HCB | 11.7 | 44.5 | 43.8
| JPT | 4.4 | 61.1 | 34.5
| YRI | 11.6 | 46.3 | 42.2
| ASW | 12.3 | 43.9 | 43.9
| CHB | 11.7 | 44.5 | 43.8
| CHD | 17.4 | 38.5 | 44.0
| GIH | 5.9 | 41.6 | 52.5
| LWK | 4.5 | 46.4 | 49.1
| MEX | 10.3 | 51.7 | 37.9
| MKK | 12.3 | 45.2 | 42.6
| TSI | 33.3 | 53.9 | 12.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4919908
|Name_s=
|Gene_s=C19orf20
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00002. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109334
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4919908
|overall_frequency_n=72
|overall_frequency_d=128
|overall_frequency=0.5625
|n_genomes=43
|n_genomes_annotated=0
|n_haplomes=56
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}